Basilea Pharmaceutica AG (SWX:BSLN)
Switzerland
· Delayed Price · Currency is CHF | Market Cap | 653.91M |
| Revenue (ttm) | 232.38M |
| Net Income (ttm) | 40.24M |
| Shares Out | 12.29M |
| EPS (ttm) | 3.14 |
| PE Ratio | 16.93 |
| Forward PE | 13.13 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 28,718 |
| Average Volume | 32,120 |
| Open | 53.00 |
| Previous Close | 53.20 |
| Day's Range | 52.00 - 54.60 |
| 52-Week Range | 42.75 - 59.70 |
| Beta | 0.43 |
| RSI | 49.78 |
| Earnings Date | Aug 18, 2026 |
About Basilea Pharmaceutica AG
Basilea Pharmaceutica AG is a Swiss commercial-stage biotech company focused on developing and commercializing treatments for severe bacterial and fungal infections. The company offers Cresemba (isavuconazole), an intravenous and oral antifungal for the treatment of invasive aspergillosis and mucormycosis; and Zevtera (ceftobiprole), an antibiotic for the treatment of pneumonia, Staphylococcus aureus bacteremia (SAB), acute bacterial skin, community-acquired bacterial pneumonia, and skin structure infections (ABSSSI). The company also has a cli... [Read more]
Financial Performance
In 2025, Basilea Pharmaceutica AG's revenue was 232.38 million, an increase of 11.43% compared to the previous year's 208.54 million. Earnings were 40.24 million, a decrease of -48.14%.
Financial StatementsNews
Basilea shareholders approve all proposals of the board of directors at the 2026 annual general meeting
Allschwil, Switzerland, April 15, 2026 Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial a...
Basilea awarded additional CARB-X funding of USD 6 million to support the clinical development of antibiotic BAL2420
Funding is awarded following successful completion of IND-enabling studies and clinical study authorization USD 6 million in additional funding to support antibiotic BAL2420 (LptA inhibitor) first-in...
Basilea announces start of first‑in‑human study of novel antibiotic BAL2420
Allschwil, Switzerland, March 23, 2026 Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial a...
Basilea receives further USD 6 million from BARDA to continue development of novel antibiotic ceftibuten-ledaborbactam
Ad hoc announcement pursuant to Art. 53 LR Allschwil, Switzerland, February 25, 2026 Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting...
Basilea Pharmaceutica AG Earnings Call Transcript: H2 2025
Revenue grew 11% to CHF 232.4 million in 2025, driven by Cresemba and Zevtera, with net profit at CHF 40.2 million and strong cash flow. Pipeline expansion and non-dilutive funding position the business for sustained growth, despite upcoming loss of exclusivity for Cresemba.
Basilea reports strong 2025 full-year results, surpassing revenue and operating profit guidance
15% royalty income increase 11% total revenue increase Tripled net cash position Phase 3 program with fosmanogepix progressing as planned Financial guidance FY 2026: Double-digit increase in total rev...
Strong Cresemba® (isavuconazole) sales performance in Asia Pacific and China triggers milestone payment to Basilea
Allschwil, Switzerland, February 09, 2026 Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacteria...
Basilea provides portfolio update and outlook
Clinical portfolio strengthened through the in-licensing of phase 3-ready antibiotic ceftibuten-ledaborbactam Fosmanogepix second phase 3 study initiated; two phase 3 studies in invasive fungal infect...
Prokaryotics and Basilea enter collaboration to develop a novel broad-spectrum antifungal for severe invasive infections
UNION, N.J., Jan. 7, 2026 /PRNewswire/ -- Prokaryotics Inc., a privately-held biopharmaceutical company engaged in the discovery and development of novel anti-infectives, today announced an agreement ...
Basilea and Phare Bio enter partnership combining anti-infectives industry expertise with unique AI capabilities for the development of a novel antibiotic
Allschwil, Switzerland, December 11, 2025 Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacteria...
Phare Bio and Basilea Announce Landmark Partnership to Develop Next-Generation Broad-Spectrum Antibiotic Using AI
BOSTON--(BUSINESS WIRE)--Phare Bio, a biotech social venture harnessing artificial intelligence to accelerate antibiotic discovery and development, and Basilea Pharmaceutica, a commercial-stage biopha...
Strong Cresemba® (isavuconazole) sales performance in Europe triggers USD 30 million milestone payment to Basilea
Ad hoc announcement pursuant to Art. 53 LR Allschwil, Switzerland, November 04, 2025 Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting...
Basilea awarded BARDA contract for the development of novel oral phase 3-ready antibiotic ceftibuten-ledaborbactam
- Total non-dilutive funding of up to USD 159 million upon completion of predefined milestones, including near-term committed funding of USD 6 million
Basilea receives USD 25 million funding under BARDA agreement to continue to advance novel antifungals fosmanogepix and BAL2062
Ad hoc announcement pursuant to Art. 53 LR Allschwil, Switzerland, September 16, 2025 Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meetin...
Basilea Pharmaceutica AG Earnings Call Transcript: H1 2025
Strong H1 2025 results driven by Cresemba's robust sales and Zevtera's U.S. launch, with total revenue up 36% year-on-year. Pipeline expanded with a new oral antibiotic, and 2025 guidance raised for revenue and operating profit, despite expected product revenue decline from Pfizer supply.
Basilea on track with strong 2025 half-year results
Cresemba ® and Zevtera ® -related revenues rise by 24% to CHF 90.5 million Total revenue grows significantly by 36% to CHF 104.0 million Operating profit surges by 160% to CHF 24.0 million Operating c...
Basilea announces in-licensing of a novel clinical phase 3-ready oral antibiotic
Ad hoc announcement pursuant to Art. 53 LR Allschwil, Switzerland, August 14, 2025 Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting t...
Assessment of the 14-Alpha Demethylase Inhibitors Pipeline Landscape 2025, Featuring Insights Into Oteseconazole (Mycovia Pharmaceuticals) and Isavuconazonium (Basilea Pharmaceutica)
Dublin, May 08, 2025 (GLOBE NEWSWIRE) -- The "14-alpha Demethylase Inhibitors - Pipeline Insight, 2025" clinical trials has been added to ResearchAndMarkets.com's offering. This report provides compre...
Strong sales for Cresemba® (isavuconazole) in Japan trigger second milestone payment from Asahi Kasei Pharma to Basilea
Allschwil, Switzerland, April 24, 2025 Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial a...
Basilea Pharmaceutica AG Earnings Call Transcript: H2 2024
2024 saw revenue grow 32% to $208.5M, with operating profit tripling and net profit reaching $77.6M. Cresemba and Zevtera drove strong results, while the pipeline expanded with new antifungal and antibiotic assets. 2025 guidance anticipates continued growth and profitability.
Basilea Pharmaceutica AG Earnings Call Transcript: H1 2024
Strong H1 2024 results driven by Cresemba growth and Zevtera U.S. approval led to raised full-year guidance. Pipeline expanded with four new anti-infective programs, and significant milestone payments are expected in H2. Debt reduction and stable expenses support a positive outlook.
US FDA approves Basilea Pharmaceutica's antibiotic
The U.S. health regulator approved Basilea Pharmaceutica's antibiotic for bacterial infections including multidrug-resistant strains, the FDA said on Wednesday.
Basilea Pharmaceutica AG Earnings Call Transcript: H2 2023
Basilea reports strong 2023 full-year results with profitability significantly above guidance, whilst substantially expanding the R&D portfolio
Increased Cresemba ® and Zevtera ® -related revenue of CHF 150.3 million (+22.9% year-on-year) at upper end of guidance Operating profit of CHF 19.2 million and net profit of CHF 10.5 million, signifi...